Nasdaq Sets Nov. 9, 2026, as Scheduled Date to Delist Charming Medical Securities
Key Facts
Nasdaq said Charming Medical Limited’s securities are scheduled to be delisted from the Nasdaq Stock Market on Nov. 9, 2026, according to an exchange notice. The date sets a scheduled delisting and does not mean the process has already been completed. The company’s Class A ordinary shares were listed on the Nasdaq Capital Market under the ticker MCTA. The notice comes while the shares are not trading on Nasdaq, following a suspension that began in November 2025. The available facts do not state the basis for the delisting decision, so it cannot be attributed to a specific listing requirement failure.
The U.S. Securities and Exchange Commission temporarily suspended trading in the company’s securities on Nov. 12, 2025, and set the suspension to expire on Nov. 25 of the same year. The SEC linked the action to the possibility of social media recommendations that appeared designed to artificially raise the share price and trading volume. According to the company’s account of the SEC report in its annual report, the recommendations included anonymous calls to buy, hold or sell the shares, along with images of transactions. The company said, "We did not authorize any promotional activity of this kind." After the temporary suspension period ended, Nasdaq announced on Nov. 26 that trading was halted pending the company’s submission of additional information in response to an exchange request.
The company said in its annual report that trading in its Class A ordinary shares had remained suspended since Nov. 12, 2025. Nasdaq reported that the last sale price before trading was halted was $29.355 per share. EL7 data records a price of $29.35 on Oct. 22, 27 and 28, 2026, but those records do not establish that trading took place on those days, given the announced continuing suspension. It is therefore not accurate to describe the Oct. 28 price as the close of an active trading session or to say the stock was unchanged on the day. The company said the continued suspension or halt could harm the liquidity and value of its shares and constrain its ability to raise equity financing and access public capital markets.
Charming Medical provides beauty and wellness products and services, as well as postpartum services, in Hong Kong, according to its filing with the Securities and Exchange Commission. Its shares began trading on the Nasdaq Capital Market on Oct. 21, 2025, after an offering of 1,600,000 shares at $4 per share. Revenue for the fiscal year ended March 31, 2026, was $4,807,713, down 22.7% from $6,221,751 in the previous year. Revenue from beauty and wellness and postpartum services fell from $5,967,277 in fiscal 2025 to $4,508,504 in fiscal 2026. The company said $2,618,481, or about 54.5% of 2026 revenue, came from contract liability balances outstanding at the beginning of the year, while $1,658,776, or about 34.5%, was recognized when unused packages expired.
The company reported a net loss of $22,648 for the fiscal year ended March 31, 2026. As of the same date, working capital surplus was $3,842,449 and cash and cash equivalents were $4,699,273, according to the annual report. Disclosures also showed $185,799 in outstanding bank loans, and the company said it currently has no bank credit facilities. Separately, the company disclosed a securities class action filed on Dec. 19, 2025, followed by an amended complaint on June 12, 2026, and said it intends to defend itself. The company gave no assurance about when the trading halt would be lifted or whether an active market for its shares would return, while the scheduled delisting date remains Nov. 9, 2026.